News
Inspirna Announces Appointment of Karim Benhadji, M.D., as Chief Medical Officer and Retirement of Robert Wasserman, M.D.
NEW YORK – May 21st, 2024 – Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class cancer therapeutics,… Read More
Inspirna to Present at the 42nd Annual J.P. Morgan Healthcare Conference
New York, NY – January 4, 2024 – Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class cancer therapeutics,… Read More
Inspirna Partners with Merck KGaA, Darmstadt, Germany, to Accelerate Global Development of Ompenaclid (RGX-202)
Inspirna to receive $45 million in upfront payment for ex-US exclusive license and US co-development option to ompenaclid… Read More
Inspirna Announces Clinical Data from Phase 1b/2 Study of Ompenaclid (RGX-202) in Advanced Colorectal Cancer at ESMO Congress 2023
Encouraging efficacy and safety data for ompenaclid (RGX-202) in combination with FOLFIRI/BEV supports further development in second-line advanced… Read More
Inspirna to Present Clinical Data from Phase 1b/2 Study of Ompenaclid (RGX-202) in Advanced Colorectal Cancer at ESMO Congress 2023
Company to host virtual KOL panel to discuss the data on Sunday, October 22, 2023 at 12:30pm ET… Read More
Inspirna to Present at the Jefferies Healthcare Conference
NEW YORK–(BUSINESS WIRE)–Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class cancer therapeutics, announced today that Chief Executive… Read More
Inspirna Appoints Dr. Usman “Oz” Azam, M.D., as New Chief Executive Officer
NEW YORK–(BUSINESS WIRE)–Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class cancer therapeutics, announced today the appointment of… Read More
Inspirna Announces Interim Data from Phase 1b/2 Study of Abequolixron (RGX-104) in Relapsed or Refractory Lung Cancer
Abequolixron in combination with docetaxel in heavily-pretreated NSCLC and SCLC is well tolerated and demonstrates encouraging preliminary clinical… Read More
Inspirna to Present at the Evercore ISI Annual HealthCONx Conference
November 17, 2022 08:00 AM Eastern Standard Time NEW YORK–(BUSINESS WIRE)–Inspirna, Inc., a clinical stage biopharmaceutical company developing… Read More
Inspirna Raises $50 Million in Series D Financing
Funding to further support company in advancing its clinical stage oncology programs NEW YORK–(BUSINESS WIRE)–Inspirna, Inc., a clinical… Read More
Inspirna to Present Phase 1b RGX-202-01 Clinical Trial Data at the 2022 ESMO World Congress on Gastrointestinal Cancer
Favorable efficacy and safety support further development of RGX-202-01 in advanced or metastatic second-line colorectal cancer NEW YORK–(BUSINESS… Read More
Inspirna to Present Phase 1b RGX-202-01 Clinical Trial Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
ORR of 50% and median PFS of 11.8 months in patients with KRAS mutant advanced colorectal cancer (CRC)… Read More
Inspirna Announces Phase 1b RGX-202 Clinical Trial Data Selected for Poster Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2022 10:00 AM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Inspirna, Inc., a clinical stage biopharmaceutical company developing… Read More
Inspirna to Present at 21st Annual Needham Virtual Healthcare Conference
New York, NY – April 7, 2022 – Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule… Read More
Inspirna to Participate in Multiple Virtual Healthcare Investor Conferences in March
New York, NY – March 8, 2022 – Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule… Read More
Inspirna Strengthens Scientific Advisory Board with Two Globally Renowned Experts in Gastrointestinal Oncology
–Drs. Josep Tabernero, M.D., Ph.D. and Alan Venook, M.D. to Support Company in Advancing Pipeline of Novel Drug… Read More
Inspirna to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
NEW YORK–(BUSINESS WIRE)–Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics, announced… Read More
Inspirna to Present at the Stifel 2021 Virtual Healthcare Conference
New York, NY – November 10, 2021 – Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule… Read More
Inspirna Announces Clinical Collaboration with Bristol Myers Squibb to Study RGX-104 in Combination with Yervoy® (ipilimumab) for Treatment of Metastatic Endometrial Cancer
NEW YORK–(BUSINESS WIRE)–Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics, today… Read More
RGENIX Announces Company Name Change to Inspirna and Expands Board of Directors with Appointment of Pharma Veteran Dieter Weinand
NEW YORK–(BUSINESS WIRE)–Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics, announced… Read More
RGENIX to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
New York, NY – November 23, 2020 – RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small… Read More
RGENIX to Present at 2020 Stifel Virtual Healthcare Conference
New York, NY – November 04, 2020 – RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced… Read More
RGENIX to Present at H.C. Wainwright 22nd Annual Global Investment Conference
New York, NY – September 02, 2020 – RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small… Read More
RGENIX to Present at Multiple Virtual Healthcare Investor Conferences in August
New York, NY – Aug 05, 2020 – RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced… Read More
RGENIX Presents Biomarker and Efficacy Results from Phase 1 Dose Escalation Cohorts of RGX-104 at the 2020 AACR Annual Meeting
New York, NY – June 22, 2020 – RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small… Read More
RGENIX Presents Results from Preclinical Safety and Efficacy Studies of RGX-019 at the 2020 AACR Annual Meeting
New York, NY – June 22, 2020 – RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small… Read More
RGENIX Shows Clinical Activity of Novel Agent RGX-202 in Patients with KRAS Mutant Colorectal Cancer in Phase 1 Trial
Data from Phase 1 Trial of RGX-202 Presented at 2020 ASCO Virtual Scientific Program New York, NY –… Read More
RGENIX To Present RGX-202 Phase I Data at 2020 ASCO Virtual Scientific Program
New York, NY – May 21, 2020 – RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small… Read More
RGENIX Presents Initial Results of Combination Trial of RGX-104 at the 2020 AACR Annual Meeting
New York, NY – April 27, 2020 – Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small… Read More
Clinical Development of First-in-class Innate IO Agents
Masoud Tavazoie, Rgenix CEO and Co-Founder speaks at Immuno-Oncology 360° From February 26th – 28th 2020, the sixth… Read More
Featured on In Vivo: “Rgenix: A Cancer Start-Up’s Resolve To Crack The Mystery Of Metastasis”
Rgenix, a New York-based start-up co-founded by three prominent physician researchers, is taking aim at what it contends… Read More
Rgenix Names Industry Veteran to Chief Medical Officer Role
Robert Wasserman, MD, joins Rgenix with more than 20 years of oncology clinical development experience and prior senior… Read More
Rgenix Presents Pre-Clinical Data on RGX-019 at the 2019 AACR Annual Meeting
Pre-clinical data demonstrates first-in-class MERTK selective inhibitor with novel mechanism of action Rgenix has initiated IND-enabling studies of… Read More
Rgenix To Present Abstract on RGX-019 at the 2019 AACR Annual Meeting
New York, NY – April 1, 2019- Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule… Read More
Translational and Clinical Development Strategies for IO Agents Targeting the Innate Immune System
Immuno-Oncology 360° | Crown Plaza Time Square, New York City | February 6, 2019 Masoud Tavazoie, Rgenix CEO… Read More
Xconomy: New York Biotech – How to make it here
6:15-6:45 PM | The Rgenix Story: From our beginnings as a small spin-out from Rockefeller University to a world-class team… Read More
Rgenix CEO Masoud Tavazoie Discusses Immune System Regulation in Cancer at Plenary Session during AACR Meeting
On November 28, 2018, Masoud Tavazoie, Co-Founder and CEO of Rgenix, made a presentation at AACR’s Tumor Immunology… Read More
Rgenix Appoints Serial Entrepreneur and Senior Executive Peter Van Vlasselaer to Board of Directors
New York, NY – Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer… Read More
AACR Tumor Immunology and Immunotherapy Conference
AACR Tumor Immunology and Immunotherapy Conference November 27 – 30, 2018 | Loews Miami Beach Hotel, Miami Beach,… Read More
Rgenix Treats First Patient in Phase 1 Trial of RGX-202
NEW YORK – Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, today announced… Read More
Rgenix Raises $40M in Series C Funding To Support Clinical Stage Oncology Programs
Lepu Holdings Limited leads the financing syndicate and is joined by existing major investors Novo Holdings A/S and… Read More
Rgenix Presents Data on Phase I Clinical Activity For RGX-104 at the 2018 ASCO Annual Meeting
RGX-104 shown to be well-tolerated and capable of generating immunologic and anti-tumor activity in advanced cancer patients. Rgenix… Read More
Rgenix To Present Data on RGX-104 Clinical Activity at 2018 ASCO Annual Meeting
New York, NY – May 31, 2018 — Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small… Read More
Pharmacodynamic and clinical activity of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies
Presentation Monday, June 4, 2018, at ASCO. RGX-104 is a small-molecule LXR agonist that modulates innate immunity via… Read More
Rgenix Announces Publication In Cell Demonstrating Activation of LXR/ApoE with RGX-104 Enhances Antitumor Immunity
LXR/ApoE Pathway Identified as Key Regulator of Innate Immune Suppression in Cancer FOR IMMEDIATE RELEASE New York, NY… Read More
Rgenix Reports Phase I Data for Cancer Compound RGX-104
Rgenix Inc. (New York, N.Y.) reported preliminary data from a Phase Ia/Ib trial showing that oral RGX-104 led… Read More
Liver X Factor
How Rgenix’s Liver X Agonist Could Help Overcome Checkpoint Resistance in Cancer. To read the full article, please click… Read More
Rgenix Reports Preliminary Phase 1a/b Clinical Data Demonstrating Immune-stimulatory Activity with RGX-104 in Advanced Cancer Patients
Preliminary Phase 1a/b data demonstrate RGX-104 modulates the innate immune system to stimulate T cell activation in a… Read More
Rgenix Reports Preliminary Phase 1a/b
Preliminary Phase 1a/b data demonstrate RGX-104 modulates the innate immune system to stimulate T cell activation in a… Read More
Rgenix to Present Early Clinical Data on RGX-104 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
New York, NY – October 26, 2017 – Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule… Read More
Meet the 30 biotech leaders under 40 who are searching for breakthrough treatments and shaping the future of medicine
It’s an exciting time to be in the biotech and pharmaceutical industries. To read the full piece, please click here. Read More
For Rgenix CEO Masoud Tavazoie, fighting cancer is a family business
Rgenix CEO Masoud Tavazoie was recently interviewed for an article in The Pharma Letter. To read the full… Read More
Rgenix Appoints Chief Medical Officer
For Immediate Release New York, NY – April 27, 2017 – Rgenix, Inc., a clinical stage biopharmaceutical company developing… Read More
Rgenix Announces Treatment of First Patient in Phase 1 Trial of RGX-104, its Lead Immuno-Oncology Therapeutic
Rgenix Announces Treatment of First Patient in Phase 1 Trial of RGX-104, its Lead Immuno-Oncology Therapeutic First-in-Class… Read More
Rgenix Announces $33 Million Series B Financing to Develop First-in-Class Cancer Therapeutics
Novo A/S and Sofinnova Partners are leading this latest financing round NEW YORK, New York ― June 15,… Read More
Events
Corporate Presentation
4Q24
Download